Skip to main content
    M

    Maravai Lifesciences Holdings Inc (MRVI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.52
    +0.54 (+7.74%)

    Market Cap: $2.59B

    Last updated: Nov 06, 2026 at 4:10 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    52%(13/25)
    Avg Surprise
    -221.28%

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$0.04
    Range$-0.00 - $0.07
    9 analysts
    Revenue Consensus
    $66M
    Range$64M - $67M
    9 analysts
    Last 12 of 25 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$0.04$-0.00 - $0.07--9--
    Sep 26
    Reported Nov 4
    		$-0.08$-0.07$-0.08 - $-0.04-14.29%Miss9
    2
    4
    30d
    		+0.0%
    Jun 26
    Reported Aug 6
    		$-0.07$-0.07$-0.08 - $-0.05+0.00%Beat6
    0
    1
    30d
    		+12.5%
    Mar 26
    Reported May 7
    		$0.01N/A-+120.00%Beat8
    3
    2
    30d
    		+112.5%
    Dec 25
    Reported Feb 25
    		$-0.04$-0.07$-0.10 - $-0.06+43.02%Beat10
    3
    3
    30d
    		+33.3%
    Sep 25
    Reported Nov 6
    		$-0.08$-0.08$-0.12 - $-0.03+0.00%Beat11
    4
    6
    30d
    		-300.0%
    Jun 25
    Reported Aug 11
    		$-0.08$-0.07$-0.12 - $-0.03-14.29%Miss12
    3
    10
    30d
    		-43.4%
    Mar 25
    Reported May 12
    		$-0.08$-0.07$-0.11 - $-0.04-14.29%Miss14
    0
    12
    30d
    		-300.0%
    Dec 24
    Reported Mar 18
    		$-0.06$-0.04$-0.06 - $-0.02-49.63%Miss15
    2
    0
    30d
    		-700.0%
    Sep 24
    Reported Nov 7
    		$-0.02$-0.01$-0.02 - $0.02-100.00%Miss13
    No revisions (30d)
    		-100.0%
    Jun 24
    Reported Aug 7
    		$-0.06$-0.00$-0.01 - $0.02-6875.00%Miss12
    No revisions (30d)
    		-11.6%
    Mar 24
    Reported May 8
    		$-0.02$-0.03$-0.03 - $-0.02+33.33%Beat11
    1
    0
    30d
    		-166.7%
    Dec 23
    Reported Feb 22
    		$0.01$-0.01$-0.02 - $0.00+200.00%Beat11
    1
    0
    30d
    		-97.1%

    Key Metrics

    Valuation
    P/E Ratio-41.78EV/EBITDAN/A
    Price/FCF-89.39xFCF Yield-1.12%
    Profitability
    Profit Margin-37.10%Operating Margin-29.40%
    ROE-33.10%ROIC-28.26%
    Financial Health
    Debt/Equity0.75xInterest Coverage13.86x
    Current Ratio4.66xQuick Ratio3.35x
    Trading Statistics
    Beta0.63Avg Volume2.39M
    52-Week High$9.4252-Week Low$2.80

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$7.75
    SMA 20$7.38
    SMA 50$7.37
    SMA 200$5.32
    EMA 10$7.53
    EMA 20$7.50
    EMA 50$7.31
    EMA 200$5.78

    MACD

    Line: 0.05Signal: 0.09Hist: -0.04

    ADX

    ADX: 13.2+DI: 21.0-DI: 25.1

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down32.0
    PSAR$8.58

    Bollinger Bands

    Upper Band$8.51
    Lower Band$6.25
    %B Position3054%(Upper)
    Band Width0.56

    RSI (14-Day)

    Neutral
    50.5

    Momentum Oscillators

    Stoch %K36.7
    Stoch %D39.8
    Williams %R-58.2
    ROC (10d)2.7%
    Momentum0.20
    CCI (20d)1.8
    MFI (14d)66.7

    Volatility Measures

    ATR (14d)$0.56(7.5%)
    StdDev (20d)0.56
    Hist Vol93.7%(High)

    Volume Flow

    VWAP$7.39
    OBV51.7M
    AD Line35.3M
    CMF (20d)0.048

    Volume Metrics

    Avg Vol (20d)2.3M
    Vol Ratio0.8x
    VWMA (20d)$7.34

    Pivot Points

    R3$8.20
    R2$7.89
    R1$7.43
    Pivot Point$7.12
    S1$6.66
    S2$6.35
    S3$5.89

    Advanced Oscillators

    TSI2.42
    Ultimate Osc43.8
    KST56.40

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$45.85M$51.44M$65.84M$49.87M$41.63M$47.40M$46.85M$56.56M$69.03M$69.42M$64.18M$74.14M
    Cost of Revenue$29.66M$30.79M$32.14M$37.02M$35.98M$39.63M$39.13M$37.17M$36.79M$38.58M$38.34M$35.11M
    Gross Profit$16.19M$20.65M$33.70M$12.84M$5.66M$7.77M$7.72M$19.39M$32.23M$30.84M$25.84M$39.03M
    Operating Expenses$36.81M$35.74M$35.86M$71.64M$46.69M$74.05M$56.89M$57.09M$197.85M$44.28M$44.70M$46.18M
    R&D$3.39M$3.70M$3.89M$3.79M$3.84M$4.88M$4.89M$4.56M$4.70M$4.92M$5.03M$4.59M
    SG&A$30.50M$32.07M$29.09M$31.58M$35.46M$38.72M$39.56M$41.24M$39.09M$40.56M$40.88M$38.48M
    Operating Income$-20,619,000$-15,089,000$-2,158,000$-58,795,000$-41,031,000$-66,278,000$-49,162,000$-37,702,000$-165,614,000$-13,440,000$-18,861,000$-7,150,000
    Interest Income$598,000$1.16M$1.87M$2.38M$2.80M$3.03M$3.23M$6.04M$7.07M$7.09M$7.21M$7.46M
    Interest Expense$4.03M$7.82M$5.75M$6.55M$6.84M$6.82M$6.78M$14.45M$13.63M$11.94M$10.86M$15.40M
    Income Before Tax$-24,075,000$-21,802,000$-6,528,000$-63,009,000$-45,149,000$-74,125,000$-52,691,000$-46,074,000$-172,144,000$-20,855,000$-22,409,000$656.19M
    Income Tax Expense$-75,000$-171,000$-151,000$6,000$-92,000$-4,288,000$162,000$-7,000$311,000$-2,435,000$271,000$766.17M
    Net Income$-24,000,000$-21,631,000$-6,377,000$-63,015,000$-45,057,000$-69,837,000$-52,853,000$-46,067,000$-172,455,000$-18,420,000$-22,680,000$-109,982,000
    EBITDA$-6,797,000$-1,734,000$10.33M$-43,702,000$-25,659,000$-54,954,000$-34,228,000$-22,515,000$-150,749,000$-711,000$-4,262,000$677.85M
    EBIT$-20,646,000$-15,141,000$-2,652,000$-58,838,000$-41,102,000$-70,340,000$-49,138,000$-37,699,000$-165,542,000$-16,002,000$-18,755,000$664.13M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MRVI

    News

    Maravai LifeSciences Reports Third Quarter 2026 Financial Results

    Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) announced its third-quarter 2026 financial results, with total revenue increasing 10.1% year-over-year to $45.9 million and mRNA revenue up 28%. The company also raised...

    BioSpace•11/5/26•Bullish

    A life science supplier raises its 2026 revenue forecast to $212M–$216M

    Maravai LifeSciences (NASDAQ: MRVI) reported strong third-quarter 2026 financial results, with total revenue up 10.1% year-over-year to $45.9 million and adjusted EBITDA turning positive at $5.8 million. The company...

    Stock Titan•11/4/26•Neutral

    Form 4 Maravai Lifesciences Holdings Inc: Rajesh Asarpota (CFO) For: 30 October

    This article reports on a Form 4 filing for Maravai Lifesciences Holdings Inc., specifically detailing a transaction involving Rajesh Asarpota, the company's CFO...

    Investing.com Nigeria•11/3/26•Neutral

    Form 4 Maravai Lifesciences Holdings Inc: Rajesh Asarpota (CFO) For: 30 October

    This article reports on a Form 4 filing for Maravai Lifesciences Holdings Inc (MRVI), indicating activity by Rajesh Asarpota, the Chief Financial Officer...

    Investing.com Canada•11/2/26•Neutral

    Maravai (MRVI) CFO has 5,466 shares withheld for taxes; his family trust holds 126,352 shares.

    Maravai LifeSciences Holdings, Inc. CFO Rajesh Asarpota had 5,466 shares of Class A common stock withheld for tax obligations related to restricted stock unit awards...

    Stock Titan•11/2/26•Neutral

    MRVI Valuation and Fair Value

    P/E
    -41.8x
    Forward P/E
    212.8x
    P/FCF
    -89.4x
    P/B
    5.7x
    See GNG's fair value

    MRVI Profitability: Margins, ROIC and FCF

    Gross margin
    39.1%
    Operating margin
    -29.4%
    Net margin
    -37.1%
    ROIC
    -28.3%
    ROE
    -33.1%
    FCF margin
    -5.9%
    FCF yield
    -1.1%

    MRVI Competitors

    CompanyTicker
    Warby Parker IncWRBY
    Neogen CorporationNEOG
    Progyny IncPGNY
    Xencor IncXNCR
    Regencell Bioscience Holdings LtdRGC
    Guardian Pharmacy Services, Inc.GRDN
    Soleno Therapeutics IncSLNO
    HUTCHMED DRCHCM

    Sector: Healthcare

    MRVI Analyst Ratings

    Consensus
    Hold
    Analysts
    8
    Strong Buy
    0
    Buy
    4
    Hold
    4
    Sell
    0
    Strong Sell
    0

    MRVI Bull Case vs Bear Case

    Bear case

    • MRVI has a -37.1% net profit margin.
    • MRVI beat EPS estimates in 25.0% of its last 8 reported quarters.

    MRVI Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    8.8%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $0.04

    MRVI Earnings Date

    MRVI reports Feb 23, 2027, after the close. The date is estimated.

    MRVI Earnings Call

    The latest MRVI earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    MRVI ETF Holders

    GNG tracks 11 ETFs that hold MRVI. The largest weights:

    1. First Trust Small Cap Growth AlphaDEX Fund (FYC), 0.50% of the fund
    2. iShares Biotechnology ETF (IBB), 0.06% of the fund
    3. iShares Russell 2000 ETF (IWM), 0.02% of the fund
    4. Vanguard Health Care Index Fund ETF Shares (VHT), 0.01% of the fund
    5. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.01% of the fund
    Open the ETF Stock Exposure tool for MRVI

    See insider activity

    Frequently Asked Questions About MRVI

    When does MRVI report earnings?

    Maravai Lifesciences Holdings Inc (MRVI) is expected to report earnings on Feb 23, 2027.

    Does MRVI pay dividends?

    Maravai Lifesciences Holdings Inc (MRVI) does not currently pay a regular dividend.

    What is MRVI's market cap?

    Maravai Lifesciences Holdings Inc (MRVI) has a market capitalization of $2.59B with a current stock price of $7.52.

    Related stocks

    Sector: Healthcare

    All stocks starting with M

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In